drugset / Trial / NCT07523763
Neoadjuvant Low-dose Immunotherapy in Locally Advanced MMR-deficient Colorectal Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Patients with clinical stage II-III dMMR/MSI colorectal adenocarcinoma will be treated with low-dose immunotherapy: nivolumab 100 mg or pembrolizumab 100 mg. The duration of treatment is 6 months.
Timeline
- Start
- 2024-03-22
- Primary completion
- 2025-12-31
- Completion
- 2027-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | 100 mg | Other |
| Subject | Pembrolizumab | Monoclonal antibody | 100 mg | Other |